{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/irritable-bowel-syndrome/prescribing-information/bulk-forming-laxatives/","result":{"pageContext":{"chapter":{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives","depth":2,"htmlHeader":"<!-- begin field db7474e4-2138-4451-871e-2b2767e3ddbe --><h2>Bulk-forming laxatives</h2><!-- end field db7474e4-2138-4451-871e-2b2767e3ddbe -->","summary":"","htmlStringContent":"<!-- begin item b4f6f11d-66c2-4962-9035-86c7da233414 --><!-- begin field 6f28b219-107c-4bae-b464-a8000110212a --><ul><li><strong>Bulk-forming laxatives</strong> (containing soluble fibre) act by retaining fluid within the stool and increasing faecal mass, stimulating peristalsis; also have stool-softening properties.<ul><li>Ispaghula husk  (also known as psyllium) or sterculia — useful first-line choice in adults when it is difficult to get adequate dietary fibre; better tolerated than bran. Must not be taken immediately before bed. Adequate fluid intake is important to reduce the risk of intestinal obstruction. Not recommended for people taking constipating drugs. Typically takes 2–3 days to take effect.</li><li>Methylcellulose — useful first-line choice in adults when it is difficult to get adequate dietary fibre; better tolerated than bran. Must not be taken immediately before bed. Adequate fluid intake is important, to prevent intestinal obstruction. Tablets swell in the mouth on contact with water. Typically takes 2–3 days to take effect.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">Ford, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">Wald, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field 6f28b219-107c-4bae-b464-a8000110212a --><!-- end item b4f6f11d-66c2-4962-9035-86c7da233414 -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","lastRevised":"Last revised in October 2020","chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","fullItemName":"Management","slug":"management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d282759d-8d22-52eb-a7c1-b8761d705027","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 048cafd7-a125-4722-aae3-bcaede45094d --><h3>Contraindications and cautions</h3><!-- end field 048cafd7-a125-4722-aae3-bcaede45094d -->","summary":"","htmlStringContent":"<!-- begin item 2ce043e0-3b2d-4146-8df4-87c2e38ca9bf --><!-- begin field eccc9c03-2c9f-48a5-bb55-8b1301d9bc70 --><p><strong>Do not prescribe laxatives if there is suspected:</strong></p><ul><li>Intestinal obstruction or perforation.</li><li>Paralytic ileus.</li><li>Colonic atony or faecal impaction (bulk-forming laxatives).</li><li>Crohn's disease or ulcerative colitis.</li><li>Toxic megacolon.</li></ul><p><strong>Prescribe laxatives with caution if there is:</strong></p><ul><li>Fluid and electrolyte disturbance — discontinue treatment if there are symptoms of fluid and electrolyte disturbance.</li><li>A history of prolonged use — due to the risk of electrolyte imbalance, such as hypokalaemia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">Ford, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field eccc9c03-2c9f-48a5-bb55-8b1301d9bc70 --><!-- end item 2ce043e0-3b2d-4146-8df4-87c2e38ca9bf -->","subChapters":[]},{"id":"67641f3e-6328-5957-ab6d-293b3f665162","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f54ffda2-4990-485c-a8ca-a80000f44797 --><h3>Adverse effects</h3><!-- end field f54ffda2-4990-485c-a8ca-a80000f44797 -->","summary":"","htmlStringContent":"<!-- begin item 301f6c07-57be-4838-a0a2-a80000f4432c --><!-- begin field b9128342-f95b-444d-8a07-a80000f44797 --><p><strong>Adverse effects of bulk-forming laxatives are generally mild and infrequent, and include:</strong></p><ul><li>Flatulence and bloating. Excessive doses or inadequate fluid intake may cause intestinal obstruction.</li><li>Note: excessive doses of laxatives may cause diarrhoea, which if prolonged, may cause electrolyte disturbances such as hypokalaemia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field b9128342-f95b-444d-8a07-a80000f44797 --><!-- end item 301f6c07-57be-4838-a0a2-a80000f4432c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}